Related Experiment Videos
Current and future strategies aiming at reducing catecholamine exposure in septic shock
Arthur Dubech1,2, Adrien Picod3,4, Alexandre Pierre1,2
1Department of Intensive Care, Centre Hospitalier Universitaire de Lille, Lille, France.
Critical Care (London, England)
|June 12, 2026
Summary
Early norepinephrine use in septic shock is vital, but prolonged exposure has risks. Catecholamine-sparing strategies, including perfusion-guided care and alternative vasopressors, aim to minimize adverse effects while maintaining tissue perfusion.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Intensive Care
Background:
- Norepinephrine is the primary vasopressor for septic shock.
- Prolonged catecholamine exposure can lead to adverse effects.
- Interest is growing in strategies to reduce catecholamine use.
Purpose of the Study:
- Review the rationale for catecholamine use in septic shock.
- Discuss the adverse effects of sustained adrenergic exposure.
- Highlight current and emerging catecholamine-sparing strategies.
Main Methods:
- Review of current evidence on vasopressor therapy in septic shock.
- Analysis of catecholamine-sparing agents and strategies.
- Discussion of perfusion-guided management and emerging therapies.
Main Results:
- Early norepinephrine initiation improves outcomes.
- Catecholamine exposure has dose-dependent adverse effects.
- Perfusion-guided strategies and non-adrenergic vasopressors (vasopressin, angiotensin II) can reduce catecholamine burden.
- Corticosteroids, methylene blue, and immunomodulatory approaches offer additional benefits.
Conclusions:
- A personalized, multimodal approach is key to reducing adrenergic burden.
- Strategies include perfusion-guided targets, non-adrenergic vasopressors, and phenotype-based selection.
- Balancing tissue perfusion with minimizing vasopressor toxicity is crucial.
Related Concept Videos
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.